Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discovery of Potent and Selective 7-Azaindole Isoindolinone-Based PI3Kγ Inhibitors.
Miles DH, Yan X, Thomas-Tran R, Fournier J, Sharif EU, Drew SL, Mata G, Lawson KV, Ginn E, Wong K, Soni D, Dhanota P, Shaqfeh SG, Meleza C, Chen A, Pham AT, Park T, Swinarski D, Banuelos J, Schindler U, Walters MJ, Walker NP, Zhao X, Young SW, Chen J, Jin L, Leleti MR, Powers JP, Jeffrey JL. Miles DH, et al. Among authors: walters mj. ACS Med Chem Lett. 2020 Sep 24;11(11):2244-2252. doi: 10.1021/acsmedchemlett.0c00387. eCollection 2020 Nov 12. ACS Med Chem Lett. 2020. PMID: 33214836 Free PMC article.
Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers.
Seitz L, Jin L, Leleti M, Ashok D, Jeffrey J, Rieger A, Tiessen RG, Arold G, Tan JBL, Powers JP, Walters MJ, Karakunnel J. Seitz L, et al. Among authors: walters mj. Invest New Drugs. 2019 Aug;37(4):711-721. doi: 10.1007/s10637-018-0706-6. Epub 2018 Dec 19. Invest New Drugs. 2019. PMID: 30569245 Clinical Trial.
Discovery of AB680: A Potent and Selective Inhibitor of CD73.
Lawson KV, Kalisiak J, Lindsey EA, Newcomb ET, Leleti MR, Debien L, Rosen BR, Miles DH, Sharif EU, Jeffrey JL, Tan JBL, Chen A, Zhao S, Xu G, Fu L, Jin L, Park TW, Berry W, Moschütz S, Scaletti E, Sträter N, Walker NP, Young SW, Walters MJ, Schindler U, Powers JP. Lawson KV, et al. Among authors: walters mj. J Med Chem. 2020 Oct 22;63(20):11448-11468. doi: 10.1021/acs.jmedchem.0c00525. Epub 2020 Jul 20. J Med Chem. 2020. PMID: 32614585
Discovery of Potent and Selective PI3Kγ Inhibitors.
Drew SL, Thomas-Tran R, Beatty JW, Fournier J, Lawson KV, Miles DH, Mata G, Sharif EU, Yan X, Mailyan AK, Ginn E, Chen J, Wong K, Soni D, Dhanota P, Chen PY, Shaqfeh SG, Meleza C, Pham AT, Chen A, Zhao X, Banuelos J, Jin L, Schindler U, Walters MJ, Young SW, Walker NP, Leleti MR, Powers JP, Jeffrey JL. Drew SL, et al. Among authors: walters mj. J Med Chem. 2020 Oct 8;63(19):11235-11257. doi: 10.1021/acs.jmedchem.0c01203. Epub 2020 Sep 16. J Med Chem. 2020. PMID: 32865410 Free article.
Design, Synthesis, and Structure-Activity Relationship Optimization of Pyrazolopyrimidine Amide Inhibitors of Phosphoinositide 3-Kinase γ (PI3Kγ).
Mata G, Miles DH, Drew SL, Fournier J, Lawson KV, Mailyan AK, Sharif EU, Yan X, Beatty JW, Banuelos J, Chen J, Ginn E, Chen A, Gerrick KY, Pham AT, Wong K, Soni D, Dhanota P, Shaqfeh SG, Meleza C, Narasappa N, Singh H, Zhao X, Jin L, Schindler U, Walters MJ, Young SW, Walker NP, Leleti MR, Powers JP, Jeffrey JL. Mata G, et al. Among authors: walters mj. J Med Chem. 2022 Jan 27;65(2):1418-1444. doi: 10.1021/acs.jmedchem.1c01153. Epub 2021 Oct 21. J Med Chem. 2022. PMID: 34672584
Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity.
Piovesan D, Tan JBL, Becker A, Banuelos J, Narasappa N, DiRenzo D, Zhang K, Chen A, Ginn E, Udyavar AR, Yin F, Paprcka SL, Purandare B, Park TW, Kimura N, Kalisiak J, Young SW, Powers JP, Schindler U, Sivick KE, Walters MJ. Piovesan D, et al. Among authors: walters mj. Mol Cancer Ther. 2022 Jun 1;21(6):948-959. doi: 10.1158/1535-7163.MCT-21-0802. Mol Cancer Ther. 2022. PMID: 35405741 Free PMC article.
Characterization of AB598, a CD39 Enzymatic Inhibitory Antibody for the Treatment of Solid Tumors.
Anderson AE, Parashar K, Jin K, Clor J, Stagnaro CE, Vani U, Singh J, Chen A, Guan Y, Talukdar P, Sathishkumar P, Juat DJ, Singh H, Kushwaha R, Zhao X, Kaplan A, Seitz L, Walters MJ, Fernandez-Salas E, Walker NPC, Bowman CE. Anderson AE, et al. Among authors: walters mj. Mol Cancer Ther. 2024 Oct 1;23(10):1471-1482. doi: 10.1158/1535-7163.MCT-23-0865. Mol Cancer Ther. 2024. PMID: 38797955 Free PMC article.
CCR9 Antagonists in the Treatment of Ulcerative Colitis.
Bekker P, Ebsworth K, Walters MJ, Berahovich RD, Ertl LS, Charvat TT, Punna S, Powers JP, Campbell JJ, Sullivan TJ, Jaen JC, Schall TJ. Bekker P, et al. Among authors: walters mj. Mediators Inflamm. 2015;2015:628340. doi: 10.1155/2015/628340. Epub 2015 Sep 20. Mediators Inflamm. 2015. PMID: 26457007 Free PMC article.
84 results